Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 4791

1.

Home safety practices to prevent child injury and its association with family and children's daily routines in Japan: A cross-sectional study.

Honda C, Naruse T, Tsuchiya-Ito R, Yamamoto N, Nagata S.

Jpn J Nurs Sci. 2019 Jun 19. doi: 10.1111/jjns.12274. [Epub ahead of print]

PMID:
31216107
2.

Dynamics of Minimal Residual Disease in Neuroblastoma Patients.

Uemura S, Ishida T, Thwin KKM, Yamamoto N, Tamura A, Kishimoto K, Hasegawa D, Kosaka Y, Nino N, Lin KS, Takafuji S, Mori T, Iijima K, Nishimura N.

Front Oncol. 2019 Jun 4;9:455. doi: 10.3389/fonc.2019.00455. eCollection 2019. Review.

PMID:
31214500
3.

Development of a Noninvasive Skin Evaluation Method for Lower Limb Lymphedema.

Sano M, Hirakawa S, Yamanaka Y, Naruse E, Inuzuka K, Saito T, Katahashi K, Yata T, Kayama T, Tsuyuki H, Yamamoto N, Takeuchi H, Unno N.

Lymphat Res Biol. 2019 Jun 18. doi: 10.1089/lrb.2018.0089. [Epub ahead of print]

PMID:
31211932
4.

Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer.

Akiyoshi T, Tanaka N, Kiyotani K, Gotoh O, Yamamoto N, Oba K, Fukunaga Y, Ueno M, Mori S.

Br J Surg. 2019 Jun 13. doi: 10.1002/bjs.11179. [Epub ahead of print]

PMID:
31197828
5.

Feasibility of genomic profiling with next-generation sequencing using specimens obtained by image-guided percutaneous needle biopsy.

Sone M, Arai Y, Sugawara S, Kubo T, Itou C, Hasegawa T, Umakoshi N, Yamamoto N, Sunami K, Hiraoka N, Kubo T.

Ups J Med Sci. 2019 Apr;124(2):119-124. doi: 10.1080/03009734.2019.1607635.

PMID:
31179853
6.

Difference in central nerve system metastasis during gefitinib or erlotinib therapy in patients with EGFR-mutated non-small cell lung cancer: a retrospective study.

Yoshida K, Kanda S, Shiraishi H, Goto K, Itahashi K, Goto Y, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Ohe Y.

J Thorac Dis. 2019 Apr;11(4):1347-1354. doi: 10.21037/jtd.2019.03.61.

7.

A case of mediastinitis with an exposed artificial blood vessel that was associated with right ventricular wall damage during treatment.

Yoshida R, Yamamoto N, Nishijima A, Maruyama E, Takikawa M, Yanagibayashi S.

Case Reports Plast Surg Hand Surg. 2019 May 10;6(1):55-59. doi: 10.1080/23320885.2019.1611435. eCollection 2019.

8.

NUPR1 acts as a pro-survival factor in human bone marrow-derived mesenchymal stem cells and is induced by the hypoxia mimetic reagent deferoxamine.

Matsunaga K, Fujisawa K, Takami T, Burganova G, Sasai N, Matsumoto T, Yamamoto N, Sakaida I.

J Clin Biochem Nutr. 2019 May;64(3):209-216. doi: 10.3164/jcbn.18-112. Epub 2019 Mar 23.

9.

Structural Insights into the Inhibition of Amyloid Fibril Formation by Fibrinogen via Interaction with Prefibrillar Intermediates.

Yamamoto N, Akai T, Inoue R, Sugiyama M, Tamura A, Chatani E.

Biochemistry. 2019 Jun 5. doi: 10.1021/acs.biochem.9b00439. [Epub ahead of print]

PMID:
31135143
10.

Pazopanib regresses a doxorubicin-resistant synovial sarcoma in a patient-derived orthotopic xenograft mouse model.

Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Miyake M, Nelson SD, Russell TA, Dry SM, Li Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Higuchi T, Singh SR, Tsuchiya H, Hoffman RM.

Tissue Cell. 2019 Jun;58:107-111. doi: 10.1016/j.tice.2019.04.010. Epub 2019 May 3.

PMID:
31133237
11.

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.

Ebata T, Shimizu T, Fujiwara Y, Tamura K, Kondo S, Iwasa S, Yonemori K, Shimomura A, Kitano S, Koyama T, Sato N, Nakai K, Inatani M, Yamamoto N.

Invest New Drugs. 2019 May 24. doi: 10.1007/s10637-019-00787-3. [Epub ahead of print]

PMID:
31124055
12.

Cytokine expression profiles in cervical mucus from patients with cervical cancer and its precursor lesions.

Otani S, Fujii T, Kukimoto I, Yamamoto N, Tsukamoto T, Ichikawa R, Nishio E, Iwata A.

Cytokine. 2019 Aug;120:210-219. doi: 10.1016/j.cyto.2019.05.011. Epub 2019 May 20.

13.

Association of Adverse Drug Events with Broad-spectrum Antibiotic Use in Hospitalized Patients: A Single-center Study.

Hagiya H, Kokado R, Ueda A, Okuno H, Morii D, Hamaguchi S, Yamamoto N, Yoshida H, Tomono K.

Intern Med. 2019 May 22. doi: 10.2169/internalmedicine.2603-18. [Epub ahead of print]

14.

Preparation of Induced Pluripotent Stem Cells Using Human Peripheral Blood Monocytes.

Isogai S, Yamamoto N, Hiramatsu N, Goto Y, Hayashi M, Kondo M, Imaizumi K.

Cell Reprogram. 2018 Dec;20(6):347-355. doi: 10.1089/cell.2018.0024.

15.

Peritoneal dissemination of ascending colon cancer demonstrating relapse-free survival for 40 months with panitumumab monotherapy: A case report.

Tokuhara K, Yamamoto N, Hishikawa H, Yoshioka K.

Int J Surg Case Rep. 2019 May 9;59:41-45. doi: 10.1016/j.ijscr.2019.05.001. [Epub ahead of print]

16.

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N.

Lung Cancer. 2019 Jun;132:126-131. doi: 10.1016/j.lungcan.2019.04.014. Epub 2019 Apr 10.

17.

Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.

Oyanagi J, Koh Y, Sato K, Mori K, Teraoka S, Akamatsu H, Kanai K, Hayata A, Tokudome N, Akamatsu K, Nakanishi M, Ueda H, Yamamoto N.

Lung Cancer. 2019 Jun;132:107-113. doi: 10.1016/j.lungcan.2019.03.020. Epub 2019 Mar 22.

PMID:
31097082
18.

Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation.

Suetsugu K, Mori Y, Yamamoto N, Shigematsu T, Miyamoto T, Egashira N, Akashi K, Masuda S.

Int J Mol Sci. 2019 May 15;20(10). pii: E2413. doi: 10.3390/ijms20102413.

19.

A "Back Light System" for Identification of Sites for Endoscopic Ultrasound-Guided Fine-Needle Aspiration in Solid Pancreatic Masses: A Prospective, Randomized Study with a Crossover Design.

Harada R, Kato H, Fushimi S, Inoue H, Uchida D, Akimoto Y, Tomoda T, Matsumoto K, Noma Y, Yamamoto N, Horiguchi S, Tsutsumi K, Okada H.

Clin Endosc. 2019 May 16. doi: 10.5946/ce.2019.004. [Epub ahead of print]

20.

Biomechanical Loading Comparison between Titanium and Unsintered Hydroxyapatite/Poly-L-Lactide Plate System for Fixation of Mandibular Subcondylar Fractures.

Sukegawa S, Kanno T, Yamamoto N, Nakano K, Takabatake K, Kawai H, Nagatsuka H, Furuki Y.

Materials (Basel). 2019 May 13;12(9). pii: E1557. doi: 10.3390/ma12091557.

21.

Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L).

Akamatsu H, Teraoka S, Morita S, Katakami N, Tachihara M, Daga H, Yamamoto N, Nakagawa K.

Clin Lung Cancer. 2019 Mar 19. pii: S1525-7304(19)30075-0. doi: 10.1016/j.cllc.2019.03.002. [Epub ahead of print]

22.

Tracing of Afferent Connections in the Zebrafish Cerebellum Using Recombinant Rabies Virus.

Dohaku R, Yamaguchi M, Yamamoto N, Shimizu T, Osakada F, Hibi M.

Front Neural Circuits. 2019 Apr 24;13:30. doi: 10.3389/fncir.2019.00030. eCollection 2019.

23.

Risk stratification for lymph node metastasis using Epstein-Barr virus status in submucosal invasive (pT1) gastric cancer without lymphovascular invasion: a multicenter observational study.

Osumi H, Kawachi H, Murai K, Kusafuka K, Inoue S, Kitamura M, Yoshio T, Kakusima N, Ishihara R, Ono H, Yamamoto N, Sugino T, Nakatsuka S, Ida S, Nunobe S, Bando E, Omori T, Takeuchi K, Fujisaki J.

Gastric Cancer. 2019 May 6. doi: 10.1007/s10120-019-00963-7. [Epub ahead of print]

PMID:
31062195
24.

Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials.

Koyama T, Kondo S, Shimizu T, Fujiwara Y, Morizane C, Sakamoto Y, Okusaka T, Yamamoto N.

Front Oncol. 2019 Apr 18;9:301. doi: 10.3389/fonc.2019.00301. eCollection 2019.

25.

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.

Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N.

Int J Clin Oncol. 2019 Jul;24(7):731-770. doi: 10.1007/s10147-019-01431-z. Epub 2019 May 2.

PMID:
31049758
26.

A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies.

Yamamoto N, Ryoo BY, Keam B, Kudo M, Lin CC, Kunieda F, Ball HA, Moran D, Komatsu K, Takeda K, Fukuda M, Furuse J, Morita S, Doi T.

Invest New Drugs. 2019 Apr 30. doi: 10.1007/s10637-019-00780-w. [Epub ahead of print]

PMID:
31041575
27.

Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.

Shibaki R, Murakami S, Matsumoto Y, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Motoi N, Kusumoto M, Yamamoto N, Ohe Y.

Med Oncol. 2019 Apr 27;36(6):49. doi: 10.1007/s12032-019-1274-0.

PMID:
31030326
28.

Corrigendum to "Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer" [Lung Cancer 121 (July) (2018) Pages 37-40].

Nishio M, Nakagawa K, Mitsudomi T, Yamamoto N, Tanaka T, Kuriki H, Zeaiter A, Tamura T.

Lung Cancer. 2019 Jun;132:160. doi: 10.1016/j.lungcan.2019.04.012. Epub 2019 Apr 24. No abstract available.

29.

Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study).

Akamatsu H, Koh Y, Okamoto I, Fujimoto D, Bessho A, Azuma K, Morita S, Yamamoto N, Nakagawa K.

Lung Cancer. 2019 May;131:128-133. doi: 10.1016/j.lungcan.2019.03.021. Epub 2019 Mar 22.

30.

Changing clinical and molecular characteristics of hepatitis E virus infection in Mie Prefecture, Japan: Disappearance of indigenous subtype 3e strains.

Nakano T, Okano H, Takahashi M, Nagashima S, Shiraki K, Oya Y, Inoue H, Ohmori S, Tsukimoto M, Ishida S, Fujimoto S, Kobayashi M, Yamawaki M, Kumagai M, Ninomiya J, Maegawa T, Kojima Y, Araki J, Hamaoka S, Horiike S, Yoshimura H, Takeuchi K, Itoh K, Akachi S, Uraki S, Yamamoto N, Ogura S, Sugimoto K, Yoshikawa K, Hasegawa H, Iwasa M, Takei Y, Okamoto H.

Hepatol Res. 2019 Apr 26. doi: 10.1111/hepr.13357. [Epub ahead of print]

PMID:
31026368
31.

Efficacy and safety of ultrasound (US) guided percutaneous needle biopsy for peripheral lung or pleural lesion: comparison with computed tomography (CT) guided needle biopsy.

Yamamoto N, Watanabe T, Yamada K, Nakai T, Suzumura T, Sakagami K, Yoshimoto N, Sato K, Tanaka H, Mitsuoka S, Asai K, Kimura T, Kanazawa H, Hirata K, Kawaguchi T.

J Thorac Dis. 2019 Mar;11(3):936-943. doi: 10.21037/jtd.2019.01.88.

32.

Dietary Calcium Intake and Hypertension: Importance of Serum Concentrations of 25-Hydroxyvitamin D.

Nakamura H, Tsujiguchi H, Hara A, Kambayashi Y, Miyagi S, Thu Nguyen TT, Suzuki K, Tao Y, Sakamoto Y, Shimizu Y, Yamamoto N, Nakamura H.

Nutrients. 2019 Apr 23;11(4). pii: E911. doi: 10.3390/nu11040911.

33.

PIM kinases facilitate lentiviral evasion from SAMHD1 restriction via Vpx phosphorylation.

Miyakawa K, Matsunaga S, Yokoyama M, Nomaguchi M, Kimura Y, Nishi M, Kimura H, Sato H, Hirano H, Tamura T, Akari H, Miura T, Adachi A, Sawasaki T, Yamamoto N, Ryo A.

Nat Commun. 2019 Apr 23;10(1):1844. doi: 10.1038/s41467-019-09867-7.

34.

Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lung Cancer, 129 (March) (2019) 55-62].

Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T.

Lung Cancer. 2019 Jun;132:157-158. doi: 10.1016/j.lungcan.2019.04.010. Epub 2019 Apr 20. No abstract available.

35.

C34 Dimeric Derivatives Utilizing Disulfide Bridges as Novel HIV-1 Fusion Inhibitors.

Kobayakawa T, Ebihara K, Honda Y, Fujino M, Nomura W, Yamamoto N, Murakami T, Tamamura H.

Chembiochem. 2019 Apr 22. doi: 10.1002/cbic.201900187. [Epub ahead of print]

PMID:
31012222
36.

Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.

Koh Y, Yagi S, Akamatsu H, Kanai K, Hayata A, Tokudome N, Akamatsu K, Higuchi M, Kanbara H, Nakanishi M, Ueda H, Yamamoto N.

Clin Lung Cancer. 2019 Mar 25. pii: S1525-7304(19)30077-4. doi: 10.1016/j.cllc.2019.03.004. [Epub ahead of print]

37.

Priority Claim: First Lymphovenous Anastomosis Performed for Breast Lymphedema in 2016 and 2017.

Giacalone G, Yamamoto T, Yamamoto N.

Ann Plast Surg. 2019 Jun;82(6):710. doi: 10.1097/SAP.0000000000001862. No abstract available.

PMID:
30994492
38.

Spatially-Decomposed Free Energy of Solvation Based on the Endpoint Density-Functional Method.

Ishii Y, Yamamoto N, Matubayasi N, Zhang BW, Cui D, Levy RM.

J Chem Theory Comput. 2019 May 14;15(5):2896-2912. doi: 10.1021/acs.jctc.8b01309. Epub 2019 Apr 16.

PMID:
30990682
39.

Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function.

Goto K, Fujiwara Y, Isobe T, Chayahara N, Kiyota N, Mukohara T, Tsubata Y, Hotta T, Tamura K, Yamamoto N, Minami H.

Cancer Sci. 2019 Jun;110(6):1987-1994. doi: 10.1111/cas.14025. Epub 2019 May 11.

40.

Bacterial Community Composition and Diversity Respond to Nutrient Amendment but Not Warming in a Maritime Antarctic Soil.

Newsham KK, Tripathi BM, Dong K, Yamamoto N, Adams JM, Hopkins DW.

Microb Ecol. 2019 Apr 15. doi: 10.1007/s00248-019-01373-z. [Epub ahead of print]

PMID:
30989354
41.

Use of a linear stapler for urethral and dorsal vein complex transection during laparoscopic total pelvic exenteration in rectal cancer.

Kondo A, Nishizawa Y, Tsunemori H, Taketani H, Yamamoto N, Okazoe H, Fujita T, Sugimoto M, Suzuki Y.

Tech Coloproctol. 2019 Apr 15. doi: 10.1007/s10151-019-01974-3. [Epub ahead of print] No abstract available.

PMID:
30982932
42.

Evaluation of the Effects of Cultured Bone Marrow Mesenchymal Stem Cell Infusion on Hepatocarcinogenesis in Hepatocarcinogenic Mice With Liver Cirrhosis.

Matsuura K, Takami T, Maeda M, Hisanaga T, Fujisawa K, Saeki I, Matsumoto T, Hidaka I, Yamamoto N, Sakaida I.

Transplant Proc. 2019 Apr;51(3):925-935. doi: 10.1016/j.transproceed.2019.03.011.

PMID:
30979485
43.

Surgical decision making based on the on-track/off-track concept for anterior shoulder instability: a case-control study.

Hatta T, Yamamoto N, Shinagawa K, Kawakami J, Itoi E.

JSES Open Access. 2019 Mar 9;3(1):25-28. doi: 10.1016/j.jses.2018.10.001. eCollection 2019 Mar.

44.

Genome sequence analysis of the fairy ring-forming fungus Lepista sordida and gene candidates for interaction with plants.

Takano T, Yamamoto N, Suzuki T, Dohra H, Choi JH, Terashima Y, Yokoyama K, Kawagishi H, Yano K.

Sci Rep. 2019 Apr 10;9(1):5888. doi: 10.1038/s41598-019-42231-9.

45.

Carbon-ion radiotherapy for lymph node oligo-recurrence: a multi-institutional study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS).

Okonogi N, Kaminuma T, Okimoto T, Shinoto M, Yamamoto N, Yamada S, Murata K, Ohno T, Shioyama Y, Tsuji H, Nakano T, Kamada T.

Int J Clin Oncol. 2019 Apr 9. doi: 10.1007/s10147-019-01440-y. [Epub ahead of print]

PMID:
30968270
46.

Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer.

Konishi T, Shinozaki E, Murofushi K, Taguchi S, Fukunaga Y, Nagayama S, Fujimoto Y, Akiyoshi T, Nagasaki T, Suenaga M, Chino A, Kawachi H, Yamamoto N, Ishikawa Y, Oguchi M, Ishizuka N, Ueno M, Yamaguchi K.

Ann Surg Oncol. 2019 Apr 8. doi: 10.1245/s10434-019-07342-7. [Epub ahead of print]

PMID:
30963400
47.

Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model.

Higuchi T, Miyake K, Oshiro H, Sugisawa N, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Chawla SP, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM.

Biochem Biophys Res Commun. 2019 May 28;513(2):326-331. doi: 10.1016/j.bbrc.2019.03.191. Epub 2019 Apr 5.

PMID:
30955860
48.

Successful treatment of pathologic femoral shaft fracture associated with large arteriovenous malformations using a 3-dimensional external fixator and teriparatide: a case report.

Takeuchi A, Matsubara H, Yamamoto N, Hayashi K, Miwa S, Igarashi K, Inatani H, Tsuchiya H.

BMC Surg. 2019 Apr 5;19(1):35. doi: 10.1186/s12893-019-0498-4.

49.

Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib.

Tamura K, Nukiwa T, Gemma A, Yamamoto N, Mizushima M, Ochai K, Ikeda R, Azuma H, Nakanishi Y.

Int J Clin Oncol. 2019 Apr 5. doi: 10.1007/s10147-019-01439-5. [Epub ahead of print]

PMID:
30953238
50.

Determining Patient Satisfaction and Treatment Desires in Patients With Musculoskeletal Sarcoma of the Knee After Joint-preservation Surgery Using a Questionnaire Survey.

Abe K, Yamamoto N, Hayashi K, Takeuchi A, Kato S, Miwa S, Igarashi K, Inatani H, Aoki YU, Higuchi T, Taniguchi Y, Tsuchiya H.

Anticancer Res. 2019 Apr;39(4):1965-1969. doi: 10.21873/anticanres.13307.

PMID:
30952740

Supplemental Content

Loading ...
Support Center